4D Molecular Therapeutics, Inc. · NASDAQ:FDMT
BVF PARTNERS L P/IL reported a 9.99% stake in 4D Molecular Therapeutics, Inc. (Schedule 13G/A)
Event Sep 30, 2026 · Filed Nov 16, 2026
BVF PARTNERS L P/IL reported a 9.99% stake in 4D Molecular Therapeutics, Inc., 5,811,860 shares, as a passive investor on Sep 30, 2026. Filed Nov 16, 2026 (Schedule 13G/A).
- Stake
- 9.99%
- Shares
- 5,811,860
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 10 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | 7.30% | 4,265,045 |
| BVF I GP LLC | 7.30% | 4,265,045 |
| BIOTECHNOLOGY VALUE FUND II LP | 2.10% | 1,153,481 |
| BVF II GP LLC | 2.10% | 1,153,481 |
| Biotechnology Value Trading Fund OS LP | 0.60% | 336,458 |
| BVF Partners OS Ltd. | 0.60% | 336,458 |
| BVF GP HOLDINGS LLC | 9.30% | 5,418,526 |
| BVF PARTNERS L P/IL | 9.99% | 5,811,860 |
| BVF INC/IL | 9.99% | 5,811,860 |
| LAMPERT MARK N | 9.99% | 5,811,860 |
Source
Download original · View original at SEC
Related
- 4D Molecular Therapeutics, Inc.
- Bvf Partners L P
- 4D Molecular Therapeutics, Inc. shareholders
- Schedule 13G/A · Bvf Partners L P · May 15, 2026
- Schedule 13G/A · Bvf Partners L P · Feb 17, 2026
- Schedule 13G/A · Bvf Partners L P · May 15, 2025
- Schedule 13G/A · Bvf Partners L P · Feb 14, 2025
- Schedule 13G/A · Novo Holdings A/S · Nov 16, 2026
- Schedule 13G · State Street Corp · Nov 10, 2026
- Form 4 · Bizily Scott · Oct 20, 2026
- Form 4 · Kirn David · Oct 7, 2026
- Form 4 · Bizily Scott · Sep 22, 2026